Literature DB >> 29269202

AGR2 diagnostic value in nasopharyngeal carcinoma prognosis.

Yuejin Li1, Weiwei Wang1, Zheliang Liu2, Yuan Jiang2, Jinping Lu3, Haitao Xie4, Faqing Tang5.   

Abstract

BACKGROUND: Anterior Gradient (AGR) 2 concentration increases in the serum of tumor patients, and their diagnostic and prognostic significances were evaluated in some tumors. The previous works showed that AGR2 high express in nasopharyngeal carcinoma (NPC) biopsy tissues. However, whether AGR2 serves as a diagnostic and prognostic marker for NPC remains unclear.
METHODS: 42 healthy volunteers, 34 breast cancer patients and 124 NPC patients were enrolled into this study, and the serum samples were collected from these healthy volunteers, breast cancer patients and NPC patients. Concomitantly, 79 frozen nasopharyngeal specimens consisted of 65 NPC tissues and 14 normal nasopharyngeal tissues were enrolled in the observation. The enzyme linked immunosorbent assay (ELISA) was used to estimate AGR2 concentration in the serum samples, and AGR2 mRNA expressions in the frozen tissue samples were detected by real time RT-PCR.
RESULTS: The real time RT-PCR results showed that AGR2 mRNA level was increased in NPC tissues compared with the normal nasopharyngeal tissues (p<0.05). The ELISA data showed that AGR2 concentration in NPC serum was significantly higher in NPC patient serums than that in the health population (p<0.05). And, AGR2 expression showed a correlation with tumor node metastasis (TNM) grade (p<0.05) and Recurrence (p<0.05). Moreover, the cumulative survival rate of patients with high concentration of AGR2 was significantly lower than that of patients with low concentration of AGR2 (p<0.05), and the cumulative hazard rate of patients with high concentration of AGR2 was significantly higher than that with low concentration of AGR2 (p<0.05).
CONCLUSION: Serum AGR2 can be used as a serum marker for clinical prognosis of nasopharyngeal carcinoma. However, serum AGR2 levels could not provide advantages in clinical practice for the differential diagnosis of cancer.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AGR2; Biomarker; Diagnostic value; Nasopharyngeal carcinoma

Mesh:

Substances:

Year:  2017        PMID: 29269202     DOI: 10.1016/j.cca.2017.12.023

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma.

Authors:  Wen Wen; Shi-Juan Mai; Huan-Xin Lin; Mei-Yin Zhang; Jia-Ling Huang; Xin Hua; Chao Lin; Zhi-Qing Long; Zi-Jian Lu; Xiao-Qing Sun; Sai-Lan Liu; Qi Yang; Qian Zhu; Hui-Yun Wang; Ling Guo
Journal:  J Transl Med       Date:  2019-06-03       Impact factor: 5.531

2.  Elevated EGFL6 modulates cell metastasis and growth via AKT pathway in nasopharyngeal carcinoma.

Authors:  Ziyu Zhu; Haosheng Ni; Bo You; Si Shi; Ying Shan; Lili Bao; Bingyue Duan; Yiwen You
Journal:  Cancer Med       Date:  2018-11-15       Impact factor: 4.452

3.  Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis.

Authors:  Thanh Truong Giang Ly; Jisoo Yun; Jong-Seong Ha; Yeon-Ju Kim; Woong-Bi Jang; Thi Hong Van Le; Vinoth Kumar Rethineswaran; Jaewoo Choi; Jae-Ho Kim; Sang-Hyun Min; Dong-Hyung Lee; Ju-Seok Yang; Joo-Seop Chung; Sang-Mo Kwon
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.